Treatment of hepatitis delta virus infection
AssigneeEiger BioPharmaceuticals, Inc.
InventorsDavid A. Cory, Ingrid Choong, Jeffrey S. Glenn
Life of this patent
Estimating the term…
Abstract
Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
Claims25
1-31. (canceled)
A method for inducing immune reactivation in a patient infected with hepatitis delta virus (HDV) and hepatitis B virus (HBV), the method comprising:
- (i) administering lonafarnib and ritonavir co-therapy to the patient, wherein the lonafarnib is administered at a dose of 25 mg BID or 50 mg BID and the ritonavir is administered at a dose of 100 mg BID to 200 mg BID;
- and
- (ii) detecting a hepatitis flare in the patient.
(canceled)
A method for inducing immune reactivation in a patient infected with HDV and HBV, the method comprising administering to the patient lonafarnib at a first dose, followed by administering lonafarnib at a second dose, wherein the second dose is lower than the first dose.
45-69. (canceled)
A unit dose form comprising lonafarnib and ritonavir, wherein the unit dose form is formulated for oral administration.
(canceled)
79-86. (canceled)
Dependencies are inferred from the claim text.